Venkat Yepuri, CPO – AMGEN
Venkat Yepuri is currently the Chief Procurement Officer of Amgen. He has broad experience in healthcare industry spanning key elements of value chain from healthcare provider to drug manufacturer.
Over the past 14 years with Amgen, Mr. Yepuri held multiple roles with increasing responsibility in functions such as Strategic Sourcing, Information Systems, Business Development and Corporate Transformation. In his last role, he facilitated cross-functional delivery of Amgen’s goal of 23% global footprint reduction. As Head of Corporate Alliance Management, Mr. Yepuri led the team managing alliances for commercial products and late-stage pipeline programs with focus on under-performing partnerships. Prior to that, he did a rotational assignment engaging with IS leadership team in developing the I.S. Strategy. For 10 of the 14 years, he was in Sourcing roles starting as Associate Director and Co-lead of P2P Alignment Initiative and ending as Executive Director of Operations Sourcing with stints in between leading Commercial Sourcing, Procurement Ops & Systems, and Site Sourcing teams.
Prior to Amgen, he co-founded a physician group purchasing company in the U.S. Earlier, with the Healthcare Association of Southern California spin-off, he ran the technology consulting program for clients such as Kaiser Permanente and also established subsidiaries in India and Malaysia focused on medical equipment sales & services.
Mr. Yepuri is active in industry trade groups and also a member of the Arts and Sciences Leadership Council at California State University Channel Islands. He has a Master’s degree in Biomedical Engineering from Case Western Reserve University and a Bachelor’s degree in Electronics & Communication from Delhi University.
He resides in Thousand Oaks, California, with his wife and two kids.
Philip Tagari, VP – R&D – AMGEN
Philip Tagari is currently Vice President of Research (Therapeutic Discovery) at Amgen Inc, the world’s largest biotechnology company. His laboratories are responsible for biologics discovery, scaffold engineering, optimization and early manufacturability assessment; medicinal, oligonucleotide and peptide chemistry; protein conjugates (ADC, peptibodies) and reagents; assay development, screening, enzymological and pharmacological characterization and profiling (in vitro), as well as structural biology, biophysics, computational and analytical chemistry, materials logistics and automation. Prior to joining Amgen in 1998, Philip was a Research Fellow at Merck Frosst (Canada) Inc, where he contributed to several programs in eicosanoid and inflammatory biology, culminating in the discovery of odanacatib and rofecoxib, as well as the clinically active leukotriene D4 receptor antagonist MK-571 and the leukotriene biosynthesis inhibitor MK-591. In addition to the elucidation of leukotriene metabolism in several species, Philip established one of the first robotic screening laboratories at Merck, building on work performed at McGill and Oxford Universities on automated image analysis, quantitative immunohistochemistry and neurotransmitter measurements in neurodegeneration and cerebrovascular research. Philip is a graduate of Gonville & Caius College, Cambridge University (UK).